• Explore /
  • Poster
  • / Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.

Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors.

Abstract Poster

Authors

Pier VItale Nuzzo

Pier Vitale Nuzzo

DFCI, Brookline, MA

Pier Vitale Nuzzo , Gregory Russell Pond , Sarah Abou Alaiwi , Amin Nassar , Ronan Flippot , Catherine Curran , Kerry L. Kilbridge , Xiao X. Wei , Bradley Alexander McGregor , Lauren Christine Harshman , Toni K. Choueiri , Guru Sonpavde

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Symptoms, Toxicities, and Whole-Person Care

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 481)

Abstract #

481

Poster Bd #

H4

Abstract Disclosures

Similar Posters

First Author: Haojie Li

First Author: Diane Damotte

First Author: Andre Rashad Kydd

Poster

2024 ASCO Genitourinary Cancers Symposium

Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.

Infusion-related reactions with immune checkpoint inhibitors in genitourinary cancers: A systematic review and meta-analysis.

First Author: Yu Fujiwara